Acute Myeloid Leukemia, Adult research hub

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

This study looks at a new drug, revumenib, combined with standard treatment for a type of blood cancer called AML. It's for patients whose AML has specific genetic changes (NPM1 or KMT2A) and who can't have strong chemotherapy.